Battle against MRSA to net pharma industry US$2bn

Melbourne, 7th March 2011 - A number of new and expensive hospital brands targeting serious infections caused by multidrug-resistant bacteria, particularly MRSA*, will launch over the next decade. These will generate revenues totalling nearly US$2bn by 2019, according to independent market analyst Datamonitor.** However, the forecasted upside provided by these pipeline products will be insufficient…

7 Mar 2011, by Informa Insights